title: Regulation of insulin receptor gene expression. Cell cycle-mediated effects on insulin receptor mRNA stability.
abstract: Posttranscriptional mechanisms play important roles in insulin receptor gene regulation; variability in cellular insulin receptor number and the growth arrest-mediated increases in insulin receptor mRNA are secondary to changes in insulin receptor mRNA stability. Therefore, further characterization of the pathways and kinetics of insulin receptor mRNA degradation were investigated. The insulin receptor mRNA in the insulin receptor-rich Hep G2 cells is more stable compared with the insulin receptor-sparse MCF-7 cells. Growth arrest results in a significant rise in insulin receptor mRNA in both cell lines. The increase in mRNA is caused by changes in mRNA stability. The half-life of the insulin receptor mRNA in growth-arrested cells is approximately three times that of proliferating cells. The insulin receptor gene contains four polyadenylation sites that produce four species of mRNA of 5.4, 6.9, 8.0, and 9.4 kilobases (kb). The mRNA species are not coordinately regulated. The ratio of the most abundant species (9.4/6.9) is significantly larger in growth-arrested cells compared with proliferating cells. By utilizing a specific cDNA probe for the 9.4-kb mRNA species, it was determined that the diminished 9.4/6.9 ratio in proliferating cells was caused by a more rapid rate of the 9.4-kb mRNA degradation. The kinetics of insulin receptor mRNA degradation were investigated. Insulin receptor mRNA levels were reduced to 56% of their base line within 6 h when growth-arrested cells were stimulated to proliferate; protein inhibition with cycloheximide completely inhibited the decline in insulin receptor mRNA.
authors.affiliation: Department of Research, McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249.
authors.forename: J R
authors.initials: JR
authors.lastname: Levy
authors.forename: V
authors.initials: V
authors.lastname: Hug
mesh_terms: D000199:Actins / Q000235:genetics; D001943:Breast Neoplasms; D006528:Carcinoma, Hepatocellular; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D015342:DNA Probes; D003609:Dactinomycin / Q000494:pharmacology; D005091:Exons; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006657:Histones / Q000235:genetics; D006801:Humans; D007700:Kinetics; D008113:Liver Neoplasms; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D011972:Receptor, Insulin / Q000235:genetics* / Q000378:metabolism; D015183:Restriction Mapping; D014407:Tumor Cells, Cultured
chemical_list: D000199:Actins; D015342:DNA Probes; D006657:Histones; D012333:RNA, Messenger; D003609:Dactinomycin; D003513:Cycloheximide; D011972:Receptor, Insulin